SCHEMBL2180337

SCHEMBL2180337

CNc1nccc(-c2cc(NC(=O)CN3CCN(c4cnccn4)CC3)c3cc(OC)ccc3c2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
HIF1A Q16665 1/20 0.43
ALDH1A1 P00352 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
MAPT P10636 4/20 0.40
LMNA P02545 3/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ZAP70 P43403 1/20 0.39
TSHR P16473 3/20 0.39
USP2 O75604 1/20 0.39
MTOR P42345 1/20 0.39
SMG1 Q96Q15 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2180443 0.90 ALDH1A1 (0.54) KDM4EHPGDHIF1AALDH1A1SMN1; SMN2
SCHEMBL2179634 0.89 TSHR (0.46) KDM4EALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL2179413 0.88 MAPT (0.41) KDM4EHPGDHIF1AALDH1A1SMN1; SMN2
SCHEMBL2176734 0.87 AURKA (0.43) KDM4EHPGDHIF1AALDH1A1SMN1; SMN2
SCHEMBL2178631 0.86 SMN1; SMN2 (0.45) KDM4EHPGDHIF1AALDH1A1SMN1; SMN2
SCHEMBL2184977 0.86 KDR (0.42) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL2178573 0.86 TP53 (0.45) KDM4EALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL2179087 0.85 KMT2A (0.42) KDM4EHPGDHIF1AALDH1A1SMN1; SMN2
SCHEMBL2180704 0.85 ATM (0.46) KDM4EALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL2180895 0.85 KCNA5 (0.43) ALDH1A1SMN1; SMN2KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173808-B2 Substituted naphthalenyl-pyrimidine compounds ARQULE, INC. (US) 2012-05-08 US claimed
US-8173808-B2 Substituted naphthalenyl-pyrimidine compounds ARQULE, INC. (US) 2012-05-08 US disclosed
US-8173808-B2 Substituted naphthalenyl-pyrimidine compounds ARQULE, INC. (US) 2012-05-08 US disclosed
WO-2011082268-A2 SUBSTITUTED NAPHTHALENYL-PYRIMIDINE COMPOUNDS ARQULE INC. (US) 2011-07-07 WO disclosed
US-20110166137-A1 Substituted Naphthalenyl-Pyrimidine Compounds ARQULE, INC. (US) 2011-07-07 US disclosed
US-20110166137-A1 Substituted Naphthalenyl-Pyrimidine Compounds ARQULE, INC. (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166137-A1 Substituted Naphthalenyl-Pyrimidine Compounds DPYD, TP53, TYMP KDM4E 2457/4885HPGD 225/4885HIF1A 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.